New drug with chemotherapy for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a new drug (IAE0972) combined with chemotherapy for people with head and neck or nasopharyngeal cancer that has returned or spread. It aims to see if the combination can shrink tumors or slow the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have either head and neck cancer (in the mouth, throat, or voice box) or nasopharyngeal cancer (behind the nose) that has come back or spread and cannot be cured by surgery or radiation.
- You have had no more than 2 prior standard treatments for your recurrent or metastatic cancer.
- You have at least one tumor that can be measured on a scan, and it's not just in an area that was previously treated with radiation.
- You are generally able to do most of your daily activities (ECOG 0 or 1) and expected to live at least 3 more months.
- Your blood counts and liver, kidney, and heart function are within acceptable ranges (checking with your doctor).
- You can use reliable contraception during the study and for 6 months after the last dose (if applicable).
- You do not have untreated brain metastases, active infections, or uncontrolled autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a new form of chemotherapy (mitoxantrone hydrochloride liposome injection) to capecitabine (a standard chemotherapy pill) helps people with advanced nasopharyngeal carcinoma live longer or control their cancer better than capecitabine alone. You may be eligible if your cancer has progressed after platinum-based chemotherapy.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.